A multicenter, multinational study to assess the safety and efficacy of antithrombin alfa [ATryn] in hereditary antithrombin (AT) deficient patients in high-risk situations for thrombosis.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

15 Feb 2013 Retrospective study analysis of two pivotal phase 3 studies presented at the February 2013 meeting of the Society for Maternal-Fetal Medicine (SMFM), according to a rEVO Biologics media release.
15 Jul 2011 Planned end date changed from 1 Aug 2007 to 1 Jul 2008 as reported by ClinicalTrials.gov.
28 Feb 2008 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com